The promising multistage TB vaccine candidate H56 could evoke IL-2+IFN-γ+TNF-α+ and IL-2+IFN-γ+-secreting CD4+ T cells so to provide protection against Mtb infection (19). Here, IL2 is linked to tuberculosis.